No 03 2018

The offer values PolyPeptide's equity at approximately CHF 1.46 billion.

Thomas Karikari’s career has taken him across three continents: from Ghana to the UK and Sweden, and then to the US. Now an Associate Professor at the University of Pittsburgh and one of Nature Index’s “rising stars in ageing research”, he is helping move Alzheimer’s blood biomarkers beyond individual markers and towards a more complete picture of disease biology.

We would like to thank our readers, subscribers and collaboration partners for a fruitful and eventful Q1 + Q2 2026, and we wish you all a most wonderful summer!

The European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.

Mendus has signed an agreement with the South Australian Health and Medical Research Institute (SAHMRI) to support preparations for the Phase 2 VITAL-TFR2 trial with the company’s lead product vididencel in chronic myeloid leukemia (CML).

Presentations at the Alzheimer's Association International Conference (AAIC) show a field moving rapidly forward both with regard to treatments and diagnostics. 

Maria Ekdahl brings more than 20 years of senior finance leadership experience, including her current role as CFO of Nasdaq Stockholm-listed pharmaceutical company, Infant Bacterial Therapeutics, and will join Biovica on October 14, 2026.